Dr. Paul Forfia Provides Perspective for Healio Article on Decision to End Phase 3 Winrevair Pulmonary Arterial Hypertension Trial Early

Paul Forfia, MD, Co-Director of the Pulmonary Hypertension, Right Heart Failure & Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Program at Temple University Hospital and Professor of Medicine at the Lewis Katz School of Medicine at Temple University, provided perspective for a Healio article about the decision to end the phase 3 HYPERION trial of Winrevair in adults with newly diagnosed pulmonary arterial hypertension (PAH) functional class two or three early due to robust positive evidence found in previous trials.